Biogen Inc. and Vanqua Bio Inc. have announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s preclinical oral C5aR1 antagonist with the potential to address a broad range of inflammatory disorders.
Vanqua Bio Inc. has synthesized C5a anaphylatoxin chemotactic receptor 1 (C5aR; CD88) antagonists reported to be useful for the treatment of autoimmune disease, cancer, infections, and cardiovascular, inflammatory and neurological disorders.
Vanqua Bio Inc. has divulged C5a anaphylatoxin chemotactic receptor 1 (C5aR; CD88) antagonists reported to be useful for the treatment of autoimmune disease, cancer, infections and cardiovascular, inflammatory and neurological disorders.
Vanqua Bio Inc. announced that its development candidate VQ-101, a best-in-class brain-penetrant small-molecule allosteric activator of glucocerebrosidase (GCase), will enter clinical development in the first quarter of next year, with an initial indication in Parkinson’s disease.
Chicago-based Vanqua Bio Inc. has raised $85 million in series B financing to accelerate development of its therapies tackling Parkinson’s and other neurodegenerative diseases. Founded in 2019, Vanqua’s technology is focused on developing small-molecule activators of glucocerebrosidase, an enzyme that regulates levels of lipids in cells.
